Public Speaking Anxiety Scale: Preliminary psychometric data and scale validation

Bartholomay, Emily M.; Houlihan, Daniel

doi:10.1016/j.paid.2016.01.026

Cited by 60 publications

(51 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Exclusion criteria included having a deficit in stereoscopic vision or problematic balance impacting the experience of VR, a severe psychiatric disorder that requires dedicated care (including severe major depression, alcohol or drug abuse, bipolarity, and psychosis), active psychoactive medication (unless stable for the last 3 months), or an ongoing or planned psychological treatment during the study duration. To be included, participants also had to score ≥60 on the Public Speaking Anxiety Scale (PSAS) (Bartholomay & Houlihan, 2016) serving as a primary outcome, corresponding to the 70th population percentile. Meeting criteria for social anxiety disorder was not an inclusion criterion, but all included participants did meet criteria, most of whom with the performance-only specifier.…”

Section: Participantsmentioning

confidence: 99%

Virtual Reality exposure therapy for public speaking anxiety in routine care: a single-subject effectiveness trial

Lindner

Dagöö²,

Hamilton

et al. 2020

Cognitive Behaviour Therapy

View full text Add to dashboard Cite

Virtual Reality (VR) can be used as a therapeutic tool to conduct efficacious in-session exposure therapy by presenting virtual equivalents of phobic stimuli, yet past hardware restrictions hindered implementation in routine care and effectiveness studies. The current study examines the effectiveness of a VR-assisted treatment protocol for public speaking anxiety with demonstrated efficacy, this time in routine care, using affordable VR hardware. Participants (n = 23) were recruited via a private clinic and treated by one of four psychologists with only minimal VR-training. Using a single-subject design and dual-slope modeling (adjusting the treatment-onset slope for treatment effects), we found a significant, large decrease in self-rated public speaking anxiety following the primary three-hour session, similar in magnitude to the previous efficacy trial. Multilevel modeling of in-session process measures suggests that the protocol works as intended, by decreasing catastrophic belief expectancy and distress, and increasing perceived performance quality. Adherence to the online transition program that followed-encouraging in-vivo exposure-was relatively poor, yet symptoms decrease continued. No change was observed over the three-month follow-up period. We conclude that VR exposure therapy can be effective under routine care conditions and is an attractive approach for future, large-scale implementation and effectiveness trials.

show abstract

Section: Participantsmentioning

confidence: 99%

Virtual Reality exposure therapy for public speaking anxiety in routine care: a single-subject effectiveness trial

Lindner

Dagöö²,

Hamilton

et al. 2020

Cognitive Behaviour Therapy

View full text Add to dashboard Cite

show abstract

“…Regarding divergent validity, the guidelines used in this article and others were correlations of 0.01-0.20 (e.g., Bartholomay & Houlihan, 2016;Levinson & Rodebaugh, 2011). All three subscales and the total score of the FAPIS were not significantly related to the Anxiety and Stress subscale on the DASS.…”

Section: Divergent Validitymentioning

confidence: 60%

Psychometric evaluation of the Functional Analytic Psychotherapy Intimacy Scale in obsessive-compulsive and related disorders

Singh

Wetterneck

O’Brien

2020

Bulletin of the Menninger Clinic

View full text Add to dashboard Cite

Functional Analytic Psychotherapy (FAP) is a contextual behavioral therapy that targets specific ideographic behaviors related to interpersonal functioning and intimacy. There is a scarcity of measures specifically focused on behavioral measurement of intimacy as well as limited studies that examine intimacy in obsessivecompulsive and related disorders (OCRDs). Leonard and colleagues (2014) created the Functional Analytic Psychotherapy Intimacy Scale (FAPIS). The purpose of this study was to investigate the validity of the FAPIS in evaluating those with OCRDs. The FAPIS and other measures of intimacy were administered to 549 nonreferred adults endorsing OCRD symptoms. Several confirmatory factor analyses were conducted to assess the best fitting factor structure, and convergent validity and divergent validity were also assessed. Given the psychometric properties of the FAPIS in this sample, future research may be helpful in assessing if the FAPIS would be beneficial in measuring change related to intimacy when working with people with OCRDs.

show abstract

“…The inclusion criteria were age between 21 and 35 years, literacy in English and computer skills, absence of current or previous history of neuropsychiatric disorders, and willingness to be video recorded. Eligible participants had scores of ≥31 on the Liebowitz Social Anxiety Scale (LSAS) [32-33], ≥60 on the Public Speaking Anxiety Scale (PSAS) [34], and ≤8 on the Alcohol Use Disorders Identification Test [35]. Those who had suicidal ideation (indicated by item 9 of the Beck Depression Inventory - 2nd edition) [36], irregular heart rhythm, gross visual or hearing impairments, psychoactive medication, or concurrent psychotherapy were excluded from the study.…”

Section: Methodsmentioning

confidence: 99%

Exposure Therapy With Personalized Real-Time Arousal Detection and Feedback to Alleviate Social Anxiety Symptoms in an Analogue Adult Sample: Pilot Proof-of-Concept Randomized Controlled Trial

Lin¹,

Lee²,

Cheung³

et al. 2019

JMIR Ment Health

View full text Add to dashboard Cite

Background Exposure therapy is highly effective for social anxiety disorder. However, there is room for improvement. Objective This is a first attempt to examine the feasibility of an arousal feedback–based exposure therapy to alleviate social anxiety symptoms in an analogue adult sample. Methods A randomized, pilot, proof-of-concept trial was conducted to evaluate the acceptability, safety, and preliminary efficacy of our treatment program. Sessions were administered once a week for 4 weeks (1 hour each) to an analogue sample of 50 young adults who reported at least minimal social anxiety symptoms. Participants in both intervention and waitlist control groups completed assessments for social anxiety symptoms at the baseline, week 5, and week 10. Results Most participants found the intervention acceptable (82.0%, 95% CI 69.0%-91.0%). Seven (14.9%, 95% CI 7.0%-28.0%) participants reported at least one mild adverse event over the course of study. No moderate or serious adverse events were reported. Participants in the intervention group demonstrated greater improvements on all outcome measures of public speaking anxiety from baseline to week 5 as compared to the waitlist control group (Cohen d=0.61-1.39). Effect size of the difference in mean change on the overall Liebowitz Social Anxiety Scale was small (Cohen d=0.13). Conclusions Our results indicated that it is worthwhile to proceed to a larger trial for our treatment program. This new medium of administration for exposure therapy may be feasible for treating a subset of social anxiety symptoms. Additional studies are warranted to explore its therapeutic mechanisms. Trial Registration ClinicalTrials.gov NCT02493010; https://clinicaltrials.gov/ct2/show/NCT02493010

show abstract

Public Speaking Anxiety Scale: Preliminary psychometric data and scale validation

Cited by 60 publications

References 18 publications

Virtual Reality exposure therapy for public speaking anxiety in routine care: a single-subject effectiveness trial

Virtual Reality exposure therapy for public speaking anxiety in routine care: a single-subject effectiveness trial

Psychometric evaluation of the Functional Analytic Psychotherapy Intimacy Scale in obsessive-compulsive and related disorders

Exposure Therapy With Personalized Real-Time Arousal Detection and Feedback to Alleviate Social Anxiety Symptoms in an Analogue Adult Sample: Pilot Proof-of-Concept Randomized Controlled Trial

Contact Info

Product

Resources

About